Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
EXPENSES
General and administrative	$ 1,145,152	$ 1,336,765	$ 3,186,575	$ 5,132,834
Research and development	123,429	1,441,598	1,242,101	3,898,061
Total expenses	1,268,581	2,778,363	4,428,676	9,030,895
LOSS FROM OPERATIONS	(1,268,581)	(2,778,363)	(4,428,676)	(9,030,895)
OTHER EXPENSE (INCOME), NET
(Gain) loss on change in fair value of warrant liabilities	(1,231)	101,112	(361,137)	(1,377,855)
Loss on change in fair value of derivative liabilities	495,693		321,080
Interest expense	408,359	367,257	808,477	1,288,908
Interest income	(48,082)		(48,082)
Loss on issuance of convertible debt			358,279
(Gain) loss on voluntary conversion of convertible debt into common stock	27,790		(56,010)	1,077,287
Loss on monthly redemptions of convertible debt into common stock			208,852
Gain on settlements of accounts payable	(348,305)		(348,305)
Loss on fixed asset disposal		21,747		21,747
Other income, net	(6,547)	(33,454)	(9,262)	(33,534)
Total other expense (income), net	527,677	456,662	873,892	976,553
LOSS BEFORE PROVISION FOR INCOME TAXES	(1,796,258)	(3,235,025)	(5,302,568)	(10,007,448)
(BENEFIT) PROVISION FOR INCOME TAXES	(2,198)		800
NET LOSS FROM CONTINUING OPERATIONS	(1,794,060)	(3,235,025)	(5,303,368)	(10,007,448)
DISCONTINUED OPERATIONS
Income (loss) from discontinued operations, net of tax		159,507		(683,008)
Loss on disposal of discontinued operations, net of tax		(619,545)	(100,000)	(619,545)
GAIN (LOSS) FROM DISCONTINUED OPERATIONS		(460,038)	(100,000)	(1,302,553)
NET LOSS	(1,794,060)	(3,695,063)	(5,403,368)	(11,310,001)
Net loss attributable to non-controlling interest from discontinued operations		(38,526)		(343,038)
Net loss available to Qualigen Therapeutics, Inc.	(1,794,060)	(3,656,537)	(5,403,368)	(10,966,963)
Deemed dividend arising from warrant down-round provision	(27,587)		(87,604)
Net loss attributable to Qualigen Therapeutics, Inc	$ (1,821,647)	$ (3,656,537)	$ (5,490,972)	$ (10,966,963)
Net loss per common share, basic - continuing operations	$ (4.70)	$ (32.01)	$ (24.48)	$ (99.64)
Net loss per common share, diluted - continuing operations	(4.70)	(32.01)	(24.48)	(99.64)
Net loss per common share, basic - discontinued operations
Net loss per common share, diluted - discontinued operations		(4.17)	(0.45)	(9.55)
Total net loss per common share, diluted	$ (4.70)	$ (36.18)	$ (24.93)	$ (109.19)
Weighted-average number of shares outstanding, diluted	387,878	101,049	220,221	100,434
Other comprehensive loss, net of tax
Net loss	$ (1,794,060)	$ (3,695,063)	$ (5,403,368)	$ (11,310,001)
Foreign currency translation adjustment from discontinued operations				(50,721)
Other comprehensive loss	(1,794,060)	(3,695,063)	(5,403,368)	(11,360,722)
Comprehensive loss attributable to noncontrolling interest from discontinued operations		(38,526)		(343,038)
Comprehensive loss attributable to Qualigen Therapeutics, Inc.	$ (1,794,060)	$ (3,656,537)	$ (5,403,368)	$ (11,017,684)